Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study

Ther Drug Monit. 2020 Apr;42(2):163-164. doi: 10.1097/FTD.0000000000000718.

Abstract

In this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg). As the patient was unable to swallow whole tablets, therapeutic drug monitoring was performed to evaluate the effect of crushing sofosbuvir-velpatasvir tablets on drug absorption and global exposure.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / therapeutic use
  • Carbamates / administration & dosage
  • Carbamates / pharmacokinetics
  • Carbamates / therapeutic use*
  • Carcinoma, Hepatocellular / surgery
  • Drug Combinations
  • Drug Monitoring / methods*
  • Female
  • Half-Life
  • Hepatitis C / drug therapy*
  • Heterocyclic Compounds, 4 or More Rings / administration & dosage
  • Heterocyclic Compounds, 4 or More Rings / pharmacokinetics
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use*
  • Humans
  • Liver Neoplasms / surgery
  • Pyrrolidines / therapeutic use
  • Quinoxalines / therapeutic use
  • Sofosbuvir / administration & dosage
  • Sofosbuvir / pharmacokinetics
  • Sofosbuvir / therapeutic use*
  • Sulfonamides / therapeutic use
  • Tablets

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Carbamates
  • Drug Combinations
  • Heterocyclic Compounds, 4 or More Rings
  • Pyrrolidines
  • Quinoxalines
  • Sulfonamides
  • Tablets
  • glecaprevir and pibrentasvir
  • velpatasvir
  • Sofosbuvir